Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...

Generate:Biomedicines is hoping to raise up to $425 million via a Nasdaq IPO, with the proceeds needed to bankroll its lead antibody through respiratory disease trials. The Flagship Pioneering-founded ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 million in an initial public offering, as listing activity in ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Ayanna Redwood-Crawford and Kaitlyn Wells A million and one things can ...

Since the launch of the Crossword in 1942, The Times has captivated solvers by providing engaging word and logic games. In 2014, we introduced the Mini Crossword — followed by Spelling Bee, Letter ...

Forbes contributors publish independent expert analyses and insights. Non-fungible tokens have transformed the art world, offering artists innovative ways to create, sell and profit from their digital ...

Katelyn is a writer with CNET covering artificial intelligence, including chatbots, image and video generators. Her work explores how new AI technology is infiltrating our lives, shaping the content ...

Leeron is a New York-based writer who specializes in covering technology for small and mid-sized businesses. Her work has been featured in publications including Bankrate, Quartz, the Village Voice, ...